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InterventionsAbstract The appropriateness of the numerous therapeutic options available for patients
with advanced or metastatic renal cell carcinoma (RCC) was evaluated in 2011, using the
RAND/University of California, Los Angeles (UCLA) appropriateness methodology to
match treatment suitability to a range of patient scenarios. However, the RCC therapeutic
area evolves rapidly and a body of new clinical data has accrued in the intervening years;
as a result the exercise was repeated in 2013 using the same methodology, expert panel and
patient scenarios. The aim of the updated assessment was to update the guidance to clinicians
and use it to develop an interactive web-based application, the Renal Cell Carcinoma
Appropriateness-based Treatment Toolkit (ReCATT).
3154 M.E. Gore et al. / European Journal of Cancer 50 (2014) 3153–3160This round of assessment achieved greater concordance concerning the appropriateness of
treatments/interventions for the clinical scenarios tested; this higher level of agreement is likely
to reflect the body of scientific evidence accrued since the previous assessment exercise. Many
of the areas of disagreement in 2011 related to the suitability of pazopanib or sunitinib
treatment; in the 2013 assessment both agents were considered appropriate treatment options
for many of the clinical scenarios assessed. Uncertain scenarios often are related to the optimal
management of metastatic RCC with clear cell histology. The use of the RAND/UCLA RCC
assessment findings to develop the ReCATT support tool will help to disseminate expert
opinion concerning best treatment practice and guide the clinical management of RCC
patients treated in the community setting.
 2014 Published by Elsevier Ltd.1. Introduction
In 2011 the RAND/University of California, Los
Angeles (UCLA) appropriateness methodology [1] was
used to integrate clinical efficacy data and expert opin-
ion, to evaluate the suitability of treatments for patients
with advanced or metastatic renal cell carcinoma (RCC)
[2]. The RCC therapeutic area evolves rapidly [3,4] and
since 2011 a new agent has been licensed and a body of
new data has accrued regarding existing therapies. The
RAND/UCLA-based assessment exercise was therefore
repeated.
The objective of this study was to update the RAND/
UCLA assessment and the resulting RCC treatment
algorithm. Repeating the assessment, using the same
methodology and expert panel, allowed the evolution
of expert opinion to be tracked. The 2013 data have
been used to support the Renal Cell Carcinoma Appro-
priateness-based Treatment Toolkit (ReCATT), an
interactive application to guide clinicians regarding the
most suitable treatment for their patient.
2. Methods
The RAND/UCLA method combines evidence-
based review with the practical experience of leading
clinicians. The assessment was conducted by an expert
RCC panel, who evaluated the applicability of various
treatment strategies to 34 clinical scenarios; the panel
members and scenarios used were those from the
revious RAND/UCLA assessment [2]. Treatments were
identified by updated systematic literature review to
January 2013.
2.1. Literature review
Systematic review of the literature considering treat-
ments/interventions for locally-advanced/metastatic
RCC involved updating the original MEDLINE search
to include English language articles published from July
2010 to January 2013 using the terms: kidney cancer,
metastatic renal cell carcinoma, carcinoma renal cell
and clinical trial; bibliography search of articlesidentified additional publications. Abstracts from the
American Society of Clinical Oncology (ASCO),
European Society of Medical Oncology (ESMO), and
European Association of Urology (EAU) websites were
also reviewed. The literature review identified data
relating to the safety and efficacy of RCC treatments.
2.2. Consensus panel
The expert panel was the same as that involved in the
2011 assessment [2] and comprised recognised European
RCC experts, with nine oncologists and two urologists
from eight countries. All were clinical researchers who
regularly publish on RCC management.
Case histories and supporting materials for the 34
scenarios and the literature review were sent to each
panel member; panel members used the materials to
score the treatment/intervention choices applicable to
each scenario. The scoring results were discussed at a
panel meeting.
2.3. Clinical scenarios
The 34 hypothetical RCC scenarios from the 2011
RAND/UCLA assessment [2] were used for this updated
exercise, to ensure consistency in approach. The scenarios
were based on patient characteristics considered to have a
material effect on treatment decisions. Patient character-
istics comprised: tumour histology (clear cell or non-clear
cell), Memorial Sloan-Kettering Cancer Centre
(MSKCC) score, surgical risk, tumour staging, prior sys-
temic therapy, and prior nephrectomy; additional infor-
mation concerning and International Metastatic Renal
Cell CarcinomaDatabase Consortium (IMDC) prognos-
tic score was included in the 2013 assessment.
2.4. Classifying and grading the appropriateness of
treatments for RCC patients
The 34 clinical scenarios and 575 treatment/interven-
tions were grouped based on 6 generic descriptions
(locally-advanced tumour; metastatic RCC with in-situ
primary tumour and prior therapy; metastatic RCC
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astatic RCC with prior nephrectomy and prior therapy;
and metastatic RCC with prior nephrectomy and no
prior therapy) before scoring. For this updated assess-
ment, treatment within a clinical trial (as included in
the 2011 exercise) was not a therapy option, to ensure
relevance to practice outside of specialist centres. Panel
members scored the appropriateness of each treat-
ment/intervention for each scenario on a scale of 1 (most
inappropriate) to 9 (most appropriate).
Median scores for each treatment/intervention for
each scenario were classified as:
(1) Appropriate: A median score of 7–9, without
disagreement.
(2) Uncertain
a. A median score of 4–6,
b. ‘Disagreement’ (at least 4 panellists scoring
low [1–3] and at least 4 panellists scoring high
[7–9]).
(3) Inappropriate: A median score of 1–3, without
disagreement.
Areas of disagreement were discussed at the panel
meeting, as per the RAND/UCLA methodology [1];
after discussion contentious options were re-scored.2.5. Assessing the impact of evidence on expert opinion
Papers identified by literature search were graded
using the Scottish Intercollegiate Guidelines Network
(SIGN) system [5]. Analyses quantified and graded the
evidence and explored associations between new grade
1 and 2 evidence and concurrence regarding treatment
recommendations; the comparison was informal and
subjective, with no statistical tests being used.
Further analyses compared the findings with those
from the 2011 assessment and evaluated the impact of
evidence changes on expert opinion; potential correla-
tion between treatments/interventions where opinion
changed and the level of evidence was explored.2.6. Renal Cell Carcinoma Appropriateness-based
Treatment Toolkit
The ReCATT toolkit was updated based on the rec-
ommendations from this assessment. The ReCATT
toolkit is currently in development and comprises an
interactive, web-based application into which clinicians
can enter patient information relating to tumour histo-
pathology and stage and the treatment being considered;
ReCATT then provides the user with information
regarding optimal treatment for the individual, based
on the 2013 RAND/UCLA RCC treatment/interven-tion appropriateness assessment, and gives advice as to
whether the treatment under consideration is suitable.3. Results
3.1. The evidence base
Literature search identified 65 reports cited as part of
the previous assessment (February 2005–July 2010) and
an additional 61 publications. A total of 123 manu-
scripts reported sufficient data to be included in the
assessment, including: 24 sunitinib studies, 27 sorafenib
studies, 14 bevacizumab studies, 7 temsirolimus studies,
15 everolimus studies, five pazopanib studies, 10 inter-
feron alpha (IFNa) studies, nine interleukin-2 (IL-2)
monotherapy studies, four studies with combination
IL-2 and IFNa, 28 studies with an IFNa combination
and 19 studies with an IL-2 combination. Literature
details are presented as Supplementary Data. Table 1
summarises the clinical benefits (objective response rate
[ORR], complete response [CR], progression-free sur-
vival [PFS] and overall survival [OS]) achieved by the
RCC treatments assessed.
In September 2012 the tyrosine kinase inhibitor
(TKI) axitinib was approved in the EU as second-line
treatment for patients with advanced RCC. At the time
of the literature search for this assessment, data from
the Phase III AXIS trial [6] showed that axitinib
achieved an ORR of 19% with no complete responses
and median PFS of 6.7 months. The data presented by
this first report were not considered sufficient to support
inclusion of axitinib in the formal RAND/UCLA
assessment; axitinib does however represent a novel
RCC treatment and a more substantial body of data will
be considered in future assessments.
Overall, 101 peer-reviewed publications supported
this assessment, with 26 considered grade 1 evidence
using the SIGN criteria [5]. The numbers and grading
of publications identified for the 2013 and 2011 assess-
ments are summarised in Fig. 1.3.2. Appropriateness of the treatment options
Fig. 2 summarises treatment preferences for RCC
patients with locally-advanced clear cell tumours, and
shows surgical intervention with no targeted therapy
to be appropriate. The 2013 assessment identified some
scenarios where TKIs were a potential treatment option
for patients with bad surgical risk. For the purpose of
the RAND/UCLA assessment an attempt was made
to standardise surgical risk using the American Society
of Anesthesiologists (ASA) classification system [7]
which considers risk in terms of the patient’s physical
status; good surgical risk was defined as ASA category
1 or 2 and bad surgical risk as ASA category 3 or 4.
Surgical risk depends on the expertise of the surgeon
Table 1
Systematic review of the efficacy of interventions for the management of renal cell carcinoma.
Treatment Cumulative
no of
patients
No of
trials
Objective response
rate (ORR), %
(range)
Complete
response (CR),
% (range)
Median progression-
free survival (PFS),
months (range)
Median overall
survival (OS),
months (range)
Sunitinib 7857 24 41.9 (17.0, 58.1) 3.5 (1.0, 6.0) 9.6 (5.5, 16.3) 23.2 (5.5, 36.3)
Sorafenib 5642 27 15.9 (5.0, 50.0) 1.8 (1.0, 2.5) 8.2 (2.1, 23.9) 24.4 (4.3, 52.1)
Bevacizumab 2761 14 24.1 (11.0, 52.0) 2.3 (1.0, 4.0) 9.0 (3.9, 11.3) 24.8 (17.2, 52.1)
Everolimus 2154 15 15.3 (1.0, 51.6) – 7.3 (2.9, 29.0) 24.2 (6.6, 43.0)
Temsirolimus 1460 7 9.8 – 5.9 (2.6, 9.1) 30.7 (9.6, 52.1)
Pazopanib 1115 5 30.0 – 8.7 (5.0, 13.0) 52.1
Interferon alpha (IFNa) 3311 10 13.8 (4.8, 3.1) 1.8 (1.0, 3.0) 4.9 (3.0, 8.0) 14.4 (6.3, 31.0)
IL2 1042 9 15.6 (6.5, 23.2) 5.7 (3.0, 23.2) 11.3 (3.1, 19.5) 16.5 (11.5, 23.0)
Interleukin-2 (IL2) + IFNa 294 4 9.3 (4.9, 16.6) 3.3 6.7 (3.1, 10.4) 12.75 (12.5, 13.0)
Nephrectomy 1447 3 19 5 12 40.2 (15.0, 57.6)
Fig. 1. The number of publications and their Scottish Intercollegiate
Guidelines Network (SIGN) evidence grading for the 2011 and 2013.
RAND/University of California, Los Angeles (UCLA) assessments.
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ing the impact of these factors was beyond the scope of
this exercise.Fig. 2. Appropriate treatment options for patients with locally-adva
red = inappropriate treatment option, and yellow = treatment options of u
disease; surgical risks are according to American Society of AnesthesiologFig. 3 summarises treatment preferences for patients
with metastatic clear cell RCC and prior nephrectomy.
Pazopanib and sunitinib were considered appropriate
for most scenarios; for non-clear cell RCC, sunitinib
was considered more appropriate than other TKIs.
Fig. 4 summarises treatment preferences for patients
with metastatic clear cell RCC with prior targeted ther-
apy, for whom everolimus and TKIs were generally con-
sidered appropriate. For patients with prior sunitinib or
pazopanib therapy, systemic everolimus was considered
most appropriate; pazopanib was generally viewed as
most appropriate for patients with prior cytokines, ever-
olimus or temsirolimus.
There was discordance of opinion regarding the role
of surgery in high-risk patients. When surgery is not
indicated the systemic treatment of choice for metastatic
disease with clear cell histology with/without prior
nephrectomy remained unclear; possible options were
pazopanib, sunitinib, sorafenib, everolimus or temsirol-
imus. This discordance of opinion may reflect the neednced renal cell carcinoma. Green = appropriate treatment option,
ncertain appropriateness (The TNM classification represents stage of
ists (ASA) classification).
Fig. 3. Appropriate treatment options for patients with metastatic renal cell carcinoma with prior nephrectomy. Green = appropriate treatment
option, red = inappropriate treatment option, and yellow = treatment options of uncertain appropriateness (The TNM classification represents
stage of disease; surgical risks are according to American Society of Anesthesiologists (ASA) classification).
Fig. 4. Appropriate treatment options for patients with metastatic renal cell carcinoma with an in situ primary tumour. Green = appropriate
treatment option, red = inappropriate treatment option, and yellow = treatment options of uncertain appropriateness (The TNM classification
represents stage of disease; surgical risks are according to American Society of Anesthesiologists (ASA) classification).
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further evaluate the best therapeutic approach.
3.3. New opinions regarding the appropriateness of
treatment options
The 575 treatments/interventions and 34 clinical sce-
narios used in 2011 were reassessed in 2013. The updatewas generally in-line with the 2011 findings but the 2013
assessment demonstrated three trends for changing
expert opinion: fewer treatments were considered appro-
priate; greater consensus was seen between experts; and
pazopanib and sunitinib were considered equally suit-
able for most clinical scenarios.
Forty-one treatment options were considered appro-
priate in 2013, as opposed to 78 in 2011; 24 cases previ-
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ate by the 2013 assessment and 23 cases previously
deemed appropriate were regarded as of uncertain suit-
ability. As a result, 439 treatments were considered inap-
propriate in 2013 (compared with 372 in 2011). In 2013,
95 of 575 (17%) treatments/interventions were classified
as of uncertain appropriateness compared with 125 of
575 (22%) in 2011.
Greater concordance between experts was also appar-
ent: in 2011 there was disagreement between panel mem-
bers regarding 26 treatments/interventions; in 2013
scoring disagreement concerning 15 treatments was
resolved during panel discussion. Most cases of dis-
agreement related to sunitinib (7 scenarios) and pazopa-
nib (5 scenarios): for sunitinib there was a substantial
increase in the volume of data available (9 manuscripts
in 2011; 24 in 2013); for pazopanib there was a dearth
of data in 2011, with the evidence base increasing sub-
stantially by 2013 (from 2 to 5 manuscripts).4. Discussion
This 2013 RAND/UCLA assessment of RCC treat-
ments/interventions identified that: surgery was gener-
ally appropriate for patients with locally-advanced
clear cell tumours; pazopanib and sunitinib were appro-
priate for most cases of metastatic clear cell RCC with
prior nephrectomy; sunitinib was preferred over other
TKIs for non-clear cell RCC with prior nephrectomy;
everolimus and the TKIs were generally appropriate
for metastatic clear cell RCC and prior targeted therapy.
The panel considered pazopanib and sunitinib to be
equally appropriate for most scenarios, reflecting the
impact of the COMPARZ study [8].
The findings of the 2013 assessment have been used to
update the ReCATT toolkit. ReCATT will provide
guidance on suitable RCC treatment options for an indi-
vidual, taking into account patient characteristics, to
inform clinicians not located in specialist centres.4.1. Appropriateness of treatment
Compared with the 2011 exercise, this assessment
achieved greater concordance between panellists with
regard to the appropriateness of treatments/interven-
tions for the clinical scenarios tested. This is likely to
reflect the larger body of scientific evidence accrued
since 2010, with the findings of a number of clinical tri-
als being reported in the intervening two years.
In the 2013 assessment, 17% of treatments/interven-
tions were considered of uncertain appropriateness,
slightly lower than the 22% identified in 2011 [2]. Most
uncertainty related to metastatic clear cell RCC with
or without nephrectomy, where there was a lack of
clarity as to whether pazopanib, sunitinib, sorafenib,
everolimus or temsirolimus was most efficacious.Though increased certainty is likely to relate to data
accrued since 2010, it is also possible that decreased
‘uncertainty’ is in part due to increased familiarity with
the RAND/UCLA methodology; this is a potential
confounder when trying to identify factors driving
changing expert opinion.4.2. Change in expert opinion
Of the 78 treatment scenarios considered appropriate
in 2011, opinion on 47 options (60% of those previously
deemed appropriate) has changed over the intervening
two years. This change reflects greater specificity regard-
ing treatments/interventions considered appropriate to
different RCC scenarios. The greater concordance
achieved in 2013 can be attributed to new evidence that
clearly demonstrates clinical benefit, particularly for the
newer targeted therapies.
It is interesting to note the correlation between
change in expert opinion and change in evidence. Of
the 26 treatment options for which there was disagree-
ment in 2011, 7 concerned the use of sunitinib; the lack
of disagreement in 2013 corresponds to the availability
of an additional 15 manuscripts of which 12 were evi-
dence grade 1 or 2 (Fig. 1).
Changing expert opinion is not unexpected in a situ-
ation where evidence has accrued over time. This 2013
assessment facilitated identification of changing opin-
ion, using the quantitative though non-statistical
RAND/UCLA methodology. Having findings from
the 2011 and 2013 assessments, in which the same expert
panel considered the same clinical scenarios and treat-
ment options, demonstrates how changes in treatment
preference correlate with the availability of high-quality
trial data.4.3. Validation of the RAND-UCLA methodology
Validation of the semi-quantitative RAND-UCLA
methodology is critical to ensuring repeatability of the
exercise and credibility of the RCC treatment-assess-
ment model as a decision tool. RAND-UCLA uses
two areas of input, clinical evidence identified by
systematic review and expert opinion. By examining
the dynamics of change over time, findings that validate
use of the methodology in the RCC setting can be
identified.
The RAND/UCLA methodology proved reproduc-
ible when assessing RCC treatments, with the level of
consensus between experts increasing over two years.
The greater specificity of the 2013 recommendations
can be correlated with the increased volume of published
evidence. The RAND/UCLA methodology allows rapid
integration of new evidence and expert opinion, to
mirror ongoing trends in treatment preferences. The
correlation between the volume and quality of the
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RAND/ULCA methodology as a formalised decision-
making tool for identifying appropriate treatments for
individual RCC patients.
Seven new RCC treatments have been licensed in
recent years [4,9]. The responsiveness of the RAND/
UCLA assessment tool to changing clinical data and
the ease of the assessment process, mean that the
methodology is ideally suited to developing treatment
algorithms in rapidly changing clinical settings such
as RCC. Though the availability of numerous treat-
ments facilitates development of tailored therapy regi-
mens [10,11], a broad understanding of the evidence
base is required to enable selection of the agent best
suited to the individual [9]. Selection of the most
appropriate treatment, necessitates that the efficacy
and safety of different therapies are considered in the
light of RCC disease characteristics and patient comor-
bidities [12]; the RAND/UCLA methodology takes
into account patient characteristics, disease status and
prior treatment.
Incorporating the RAND/UCLA RCC treatment
assessment findings into an online support tool, in the
form of ReCATT, will facilitate dissemination of best-
practice from expert centres into the wider clinical-
oncology community; the ReCATT tool will guide com-
munity oncologists as to suitable RCC management reg-
imens for the individual, by taking into account patient-
specific factors that impact on treatment suitability.5. Conclusions
During the 2013 consensus meeting concordance was
reached regarding 26 treatment options for which there
was disagreement during the 2011 exercise. Many areas
of disagreement in 2011 related to the suitability of paz-
opanib or sunitinib treatment; in the 2013 assessment
these agents were both considered appropriate to many
clinical scenarios. Areas of uncertainty among RCC
experts still exist. For instance, when surgery is not indi-
cated the systemic treatment of choice for metastatic
clear cell disease with or without prior nephrectomy
remains unclear.
The availability of data from large clinical trials has a
rapid impact on how RCC experts treat patients; how-
ever advances may not translate into general oncology
practice. The use of the RAND/UCLA RCC assessment
findings to develop the online ReCATT support tool
will help disseminate expert opinion on management
practices and ensure that RCC patients treated in the
community receive optimal therapy.Role of the funding source
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